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Investigating Ebola virus pathogenicity
using molecular dynamics
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and Mark N. Wass1*
From VarI-SIG 2016: identification and annotation of genetic variants in the context of structure, function, and disease
Orlando, Florida, USA. 09 July 2016
Abstract
Background: Ebolaviruses have been known to cause deadly disease in humans for 40 years and have recently
been demonstrated in West Africa to be able to cause large outbreaks. Four Ebolavirus species cause severe disease
associated with high mortality in humans. Reston viruses are the only Ebolaviruses that do not cause disease in
humans. Conserved amino acid changes in the Reston virus protein VP24 compared to VP24 of other Ebolaviruses
have been suggested to alter VP24 binding to host cell karyopherins resulting in impaired inhibition of interferon
signalling, which may explain the difference in human pathogenicity. Here we used protein structural analysis and
molecular dynamics to further elucidate the interaction between VP24 and KPNA5.
Results: As a control experiment, we compared the interaction of wild-type and R137A-mutant (known to affect
KPNA5 binding) Ebola virus VP24 with KPNA5. Results confirmed that the R137A mutation weakens direct VP24-KPNA5
binding and enables water molecules to penetrate at the interface. Similarly, Reston virus VP24 displayed a weaker
interaction with KPNA5 than Ebola virus VP24, which is likely to reduce the ability of Reston virus VP24 to prevent host
cell interferon signalling.
Conclusion: Our results provide novel molecular detail on the interaction of Reston virus VP24 and Ebola virus VP24
with human KPNA5. The results indicate a weaker interaction of Reston virus VP24 with KPNA5 than Ebola virus VP24,
which is probably associated with a decreased ability to interfere with the host cell interferon response. Hence, our
study provides further evidence that VP24 is a key player in determining Ebolavirus pathogenicity.
Keywords: Ebola, Molecular dynamics, Virology, Protein structure, Pathogenicity
Background
The potential of Ebolaviruses to cause large outbreaks
has been highlighted by the recent Ebola virus outbreak
in West Africa [1] resulting in 28,657 confirmed cases
and 11,325 deaths as of 8th May 2016 (http://
www.who.int/csr/disease/ebola/en/). To enable replica-
tion, viruses depend on mechanisms to antagonise the
host cell interferon response. The Ebolavirus proteins that
are known to be crucially involved in the suppression
of interferon signalling are VP35 and VP24 [2–6]. VP35
prevents interferon signalling by binding and masking
double stranded viral RNA. VP24 impairs the host inter-
feron response by binding to the karyopherins α1 (KPNA1),
α5 (KPNA5) and α6 (KPNA6) and the transcription factor
STAT1 [3–5]. Karyopherins would normally bind STAT1
and transport it to the nucleus, a key step during inter-
feron signalling. VP24 prevents this transport and the sub-
sequent accumulation of STAT1 in the nucleus [2–6].
Of the five known Ebolavirus species, only Reston
viruses are not pathogenic in humans [7]. A recent
study identified genetic variants, that result in amino
acid substitutions between the four human-pathogenic
Ebolavirus species and Reston viruses that may explain
the discrepancy in human pathogenicity [8]. Certain
amino acid changes (T131S, M136 L, Q139R – Ebola virus
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residue listed first and Reston virus residue second) in the
VP24-karyopherin interface (Fig. 1) were proposed to
reduce the affinity of Reston virus VP24 to human kar-
yopherins resulting in a (compared to other Ebolavirus
VP24 proteins) reduced ability to inhibit interferon
signalling.
In this study, we compared the interaction of Ebola virus
and Reston virus VP24 with human KPNA5 using protein
structural analysis and molecular dynamics simulations.
Results
Analysis of the effect of Ebola VP24 mutations on
interaction with KPNA5
The crystal structure of the Ebola virus VP24 complex with
KPNA5 is available [3] as well as co-immunoprecipitation
studies that have investigated the effect of mutations
on the ability of Ebola virus VP24 to bind KPNA5.
The experimental data has shown that the Ebola virus
VP24 mutations R137A and the combination of
R137A,T138A,Q139A strongly reduce VP24-KPNA5
binding. Combined F134A,M136A mutations resulted
in an intermediate level of VP24-KPNA5 binding. Other
single point mutations (including Q139A that we used as
a control) had limited effect on VP24-KPNA5 binding [3].
Initially, we used mCSM [9] and FoldX [10] to predict
the effect of the investigated mutations on the stability
of the Ebola virus VP24-KPNA5 complex (mCSM, FoldX)
and the affinity of the proteins (mCSM) (see methods).
mCSM predicted that both point mutations, R137A and
Q139A, reduce the binding affinity and the stability of the
complex, with the R137A mutation, however, having a
greater effect (predicted (ΔΔG −1.07 kcal/mol change in
complex affinity) than Q139A (Table 1). Note that for
mCSM negative ΔΔG values indicate that the mutation is
predicted to destabilise the interaction, while positive values
stabilise the interaction. The FoldX predictions agree with
mCSM for both point mutations. Additionally, FoldX was
able to consider combinations of mutations simultaneously
and predicted that both sets of mutations (F134A,M136A,
and R137A,T138A,Q139A) reduce stability of the complex
with a large reduction of more than −7 kcal/ml for the
F134A, M136A combination (Table 1). These predictions
are generally in agreement with the experimental observa-
tions that R137A and the two sets of multiple mutation
Fig. 1 Ebola virus VP24 complex with KPNA5. VP24 is coloured grey and KPNA5 is blue. Residues differentially conserved between Ebola and
Reston viruses are shown in red (present in interface), orange (not in the interface site), they are and labelled with the Ebola virus amino acid,
residue number followed by the Reston virus amino acid
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reduce binding of Ebola VP24 with KPNA5 and that
Q139A results in less pronounced effects [3].
Next, molecular dynamics simulations (MD) for
both the wild type Ebola virus VP24 and mutated
forms were performed. MD simulations were ob-
tained for the wild type complexes and for the mu-
tated Ebola virus VP24 forms: 1)R137A, 2)Q139A,
3)F134A,M136A and 4)R137A,T138A,Q139A. First the
amount of positional fluctuation during the simulation for
each residue in VP24 and KPNA5 was considered by
calculating the Root Mean Squared Fluctuation (RMSF;
Fig. 2). This analysis showed that for all four mutation
sets, a greater fluctuation variability is observed in KPNA5.
Additionally, for all mutations there is increased fluctuation
in VP24 in the interface and in the vicinity of the mutated
residues (Fig. 2). This fluctuation is much greater for the
three sets of mutations that have an effect on the inter-
action between VP24 and KPNA5 and smallest for Q139A,
which affects binding to a lesser extent (Fig. 2).
Investigating the effects of VP24 R137A mutation on
interaction with KPNA5
According to the experimental data from Xu et al. [3]
the single point mutation R137A is the only point muta-
tion that largely removes binding of VP24 to KPNA5.
Thus, we used this mutation to validate our system and
to obtain additional molecular information on the inter-
action between the two proteins. The RMSF calculations
(Fig. 2) indicated the greatest movement compared to
the wild type VP24 centred around residue 115 and also
from residues 135 to 150.
To consider how this mutation affects the interaction be-
tween VP24 and KPNA5, we analysed the correlation of
conformational changes within the complexes and
investigated the solvation properties at the interface. The
solvation properties for the wild type and R137A-mutated
VP24 complexes with human KPNA5 were calculated by
estimating the water density on a grid of points constructed
around the residues at the interface (see methods). This
analysis gave a detailed description of how the solvation in-
fluences the binding of VP24 and KPNA5 (Fig. 3).
By considering how frequently each grid point (repre-
sented as spheres in Fig. 3) was visited by water mole-
cules, we were able to identify solvation sites at the
interface in a continuum range from “low density” grid
points (short temporal permanence [ps] of water mole-
cules, red spheres in Fig. 3) to “high density” grid points
(long temporal permanence [ns] of water molecules,
blue spheres in Fig. 3).
In the wild type Ebola virus complex, high density grid
points were found close to the residues N185, H186,
Fig. 2 Root Mean Square Fluctuation (RMSF) for simulation of mutated Ebola virus VP24 with human Karyopherin RMSF for the mutants over the
wild type complex. EBOV VP24 (on the left side of each graph) and KPNA5 (on the right) are shown. In black line the wild type complex RMSF is
shown; in A), the red line shows R137A mutant, in B) the blue line shows the Q139A, in C) the magenta shows F134A-M136A mutant, in D) in
cyan R137A-Q139A mutant are shown. In light blue the residues that are occurring at the interface are mapped under each curve
Table 1 Predicted effect on Ebola VP24-KPNA5 complex stability
by mutations in Ebola VP24
Mutation mCSM stability
(ΔΔG - kcal/
mol)
mCSM PP affinity
(ΔΔG - kcal/
mol)
FoldX stability
(ΔΔG - kcal/
mol)
R137A −0.80 −1.07 −0.68
Q139A −0.39 −0.24 −0.33
F134A,M136A NA NA −7.3
R137A,T138A,Q139A NA NA −1.02
Prediction from mCSM (stability and affinity) and FoldX (stability) were
calculated for the mutated complexes
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E203, P204 and D205 (Fig. 3). This means that at the
interface there are solvation sites where water molecules
are trapped and contribute to stabilise the complex. In
contrast, the mutant R137A VP24-KPNA5 complex at
the interface is characterised only by low density grids
points, meaning that water molecules do not strongly lo-
calise stably at this spot and consequently they are not
likely to contribute to the stabilisation of the complex.
The mutation induces a long-range destabilisation of the
complex creating a cleft at the interface where water
molecules can freely enter and exit (Fig. 3b). This is an
indication that the fit of the two protomers at the inter-
face of the complex is not optimal. We interpret this
conformational change as an early event of the detach-
ment of the two proteins.
The correlation of conformational changes between
VP24 and KPNA5 were considered next. Previous studies
have found that the binding of a protein ligand to a protein
receptor can result in correlated enthalpic backbone mo-
tions [11]. Consequently, a model of signal propagation
built on the analysis of local motions was generated. These
were extracted from the molecular dynamics simulations
by encoding trajectories into sequences of 4-residue frag-
ment states with the M32 K25 structural alphabet ([12]; see
materials and methods for a full description of the numer-
ical procedure used) to estimate the propensity of the Ebola
virus VP24 R137A mutant to remain bound to KPNA5.
The local error of the structural alphabet fit for the three
complexes is shown in Additional file 1: Figure S3.
The Ebola virus VP24-KPNA5 and Ebola virus
VP24(R137A)-KPNA5 complexes were encoded with
the M32 K25 structural alphabet and their collective
motions were analysed. We assessed the quality of fragment
encoding of the simulations by measuring the local fit root-
mean square deviation of the fragments from the atomistic
trajectories (Fig. 3). We found that the fragment-based en-
coding produced simplified trajectories with a reasonable
special accuracy (>1.0 Å) for each of the trajectories ana-
lysed. A statistical analysis of the global collective motions
revealed that the Ebola virus VP24-KPNA5 complex dis-
played structurally correlated motions between distal frag-
ments (Fig. 4a). The molecular dynamics simulation of the
mutant VP24(R137A)-KPNA5 interaction displayed fewer
such collective motions between the two subunits in the
dimer (Fig. 4b). In support of this observation, a topological
analysis of the three simulations revealed that the Ebola
virus wild type VP24 complex displayed a denser network
of inter-subunit correlations than the VP24(R137A)
Fig. 3 Solvation analysis of the VP24-KPNA5 complexes. In parts a, b and c the spheres represent the most visited grid points coloured from red
to blue, with red being a low density grid point (short temporal permanence [ps] of water molecules) and blue a high density grid points (long
temporal permanence [ns] of waters). a) High density grid points were found close to the residues N185, H186, E203, P204 and D205 in the Ebola
virus VP24 with human KPNA5 complex. b) The Ebola virus mutant R137A VP24-KPNA5 complex at the interface is characterized only by low density
grids points meaning that waters are not trapped and consequently do not contribute to the stabilization of the complex. The mutation induces a
long-range destabilization of the complex determining the creation of a cleft at the interface where waters can freely enter and exit. c) For the Reston
virus VP24 complex, the analysis of solvation at the interface identified high-density grid points close to the residues E203, P204, D205, D124 and R137
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complex (Fig. 4). Taken together, the physical model pre-
sented here would suggest that the wild type Ebola virus
complex is molecularly optimised for dimerisation, whereas
we predict that the mutant VP24(R137A) is unlikely to
form a stable complex, which is in agreement with the ex-
perimental data from Xu et al. [3].
Comparison of Ebola virus and Reston virus VP24
interaction with KPNA5
Next, the complex formed between Reston virus VP24
and KPNA5 was investigated with the aim of identifying
how the interaction between these two proteins may dif-
fer from the interaction between Ebola virus VP24 and
KPNA5. Only an unbound structure of Reston VP24
was available. Hence, a model of Reston virus VP24
bound to KPNA5 was generated using the Ebola virus
VP24-KPNA5 complex as a template (see Methods).
mCSM predicted that all of the conserved amino acid
changes observed in Reston virus VP24 would reduce
the stability and affinity of the complex, with the excep-
tion of M136 L, where a small increase in affinity was
predicted (Table 2). The other changes in stability were
similar to the predicted change for R137A, which is
known to reduce binding [3]. FoldX also predicted re-
duced stability for two (T131S, N132 T) of these four
point changes, with increased stability predicted for
M136 L and Q139R, although the ΔΔG for M136 L is
predicted to be very small (0.18 kcal/mol). FoldX also
predicted a slightly less stable complex with all four
amino acid changes present (Table 2). Overall these pre-
dictions suggest that together the amino changes at the
Reston virus VP24-KPNA5 interface are likely to reduce
the stability and affinity of the complex.
The interfaces of the Ebola virus VP24- and Reston
virus VP24-KPNA5 complexes were compared (Table 3)
at the beginning and end of the molecular dynamics
simulation using PISA [9] and POPSCOMP [10]. Both
complexes are stabilised by patterns of hydrogen bonds.
In the X-ray structure of the Ebola virus VP24-KPNA5
complex, nine hydrogen bonds were present, while in
the model of the Reston virus VP24-KPNA5 complex 11
hydrogen bonds were identified to form at the interface.
In total three hydrogen bonds were equivalent in the
two complexes for the energy minimised structures (i.e. at
0 ns). Molecular dynamics simulations for Ebola or Reston
virus VP24 in complex with KPNA5 were then performed
for 600 ns. We calculated the number of hydrogen bonds
Fig. 4 Correlation of conformational Changes in the VP24-KPNA5 molecular dynamics simulations. All-atom molecular dynamic simulations of a)
Ebola VP24, b) Ebola VP24 R137A (shown in red) and c) Number of inter-subunit correlations at different path lengths d) Reston VP24 with human
KPNA5 complex were encoded with the M32 K25 structural alphabet and analysed for global correlated motions between distal backbone frag-
ments. The top 10% most significant correlated motions were selected and are represented by yellow strings
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at the interface over the whole trajectory (600 ns) for both
complexes (Additional file 1: Figure S4). From the prob-
ability distribution of the number of hydrogen bonds over
the time, we observed that the Ebola virus VP24-KPNA5
complex is stabilised by 22 hydrogen bonds on average
compared to 18 for the Reston virus VP24-KPNA5 com-
plex (Additional file 1: Figure S4). So during the simula-
tion the complexes have a greater number of hydrogen
bonds than the starting structures. The four fewer
hydrogen bonds at the interface of the Reston virus
VP24-KPNA5 would suggest that this complex is ener-
getically weaker than the Ebola virus VP24-KPNA5
complex. Analysis of the simulations highlighted that in
the Ebola virus VP24 complex there was a considerable
hydrogen bonding network with KPNA5 (Fig. 5b) in-
volving VP24 residues 137–140. However, in the Reston
virus VP24-KPNA5 complex there was only limited
hydrogen bonding of VP24 R137 and T138 with KPNA5
D480 (Fig. 5b). In addition, the Ebola virus VP24-KPNA5
complex contains a hydrogen bond between VP24 Q139
and KPNA5 E474. In contrast, VP24 R139 points away
from KPNA5 and towards the solvent in the Reston virus
VP24-KPNA5 throughout the simulation (Fig. 5b).
Throughout the simulation, the RMSD of the main
chain C-Alphas was stable for both complexes (Additional
file 1: Figure S1). The RMSD of the Reston virus VP24-
KPNA5 model is greater than of the Ebola virus VP24-
KPNA5 complex, (Additional file 1: Figure S1). This could
indicate a difference in the interaction between RESTV
VP24 and KPNA5 and could also partly reflect that the
simulation is based on a model rather than a solved
structure.
For VP24 some minor differences in fluctuation
(RMSF) were observed between the Reston virus and
Ebola virus proteins. Two of these differences coincided
with the interface site at residue 113 (Fig. 2a). Residue
113 is located in an alpha helix at the interface. For
KPNA5 there are larger differences in RMSF in four re-
gions, three of which coincide with the complex inter-
face (Fig. 2a). The most pronounced difference is around
residues 477–479 (a loop region between two alpha heli-
ces), where there is very little fluctuation of KPNA5 in
the Ebola virus VP24 complex (around 1 Å) but a peak
fluctuation of 8 Å in the Reston virus VP24 complex.
The greater fluctuation in KPNA5 suggests that the
interaction with Reston virus VP24 differs from that with
Ebola virus VP24, supporting the evidence that Reston
virus VP24 and human KPNA5 are weaker binding part-
ners than Ebola virus VP24 and human KPNA5.
Analysis of the secondary structure (using DSSP [13];
see methods) during the simulation revealed minor
changes in the VP24 secondary structure occurring at
the interface site (Additional file 1: Figure S2). The most
important changes were found around residue 76 where
there is a prevalence of turns in Ebola virus VP24 which
is a coiled structure in Reston virus VP24. Residues 133
and 134 (Additional file 1: Figure S2), as well as residue
146, which are proximal to the binding interface, lose
their bend and beta bridge structures to become un-
structured in the Reston virus complex. The largest
changes in secondary structure were found in KPNA5,
particularly in two regions between residues 365–375
and 385–395 (Additional file 1: Figure S2). The second
region, which is involved in binding VP24, loses alpha
helical structure after 220 ns in the Reston virus com-
plex and changes to a turn structure instead.
For the Reston virus VP24-KPNA5 complex, analysis
of solvation at the interface identified high-density grid
points (visited by permanent water molecules) close to
the residues E203, P204, D205, D124 and R137 (Fig. 3c).
As in the case of the wild type Ebola virus VP24-KPNA5
complex, at the interface there are solvation sites where
water molecules are trapped and contribute to the
Table 3 PISA and POSPCOMP Interface Analysis at 0 and 600 ns
MD snapshots
Ebola
VP24–KPNA5
complex
Reston
VP24–KPNA5
complex
PISA results
PISA results at 0 ns
Interface Area (Å2) 1099.7 1055.1
Solvation Free Energy (ΔiG, Kcal/M) −8.5 −8.6
Hydrogen bonds 9 11
PISA results at 600 ns
Interface Area (Å2) 1119.2 1076
Solvatation Free Energy (ΔiG, Kcal/M) −10 −9.1
Hydrogen bonds 7 11
POPSCOMP results after minimisation
Hydrophobic difference (Å2) 1042.28 1002.35
Hydrophilic difference (Å2) 772.73 713.95
Total difference (Å2) 1815.06 1716.43
Table 2 Predicted effect on Ebola virus VP24-KPNA5 complex
stability by mutation of residues that are differentially conserved
in Reston in Ebola VP24
Mutation mCSM stability
(ΔΔG - Kcal/
mol)
mCSM PP affinity
(ΔΔG - Kcal/
mol)
FoldX stability
(ΔΔG - Kcal/
mol)
T131S −1.29 −0.32 −0.42
N132 T −0.62 −2.65 −1.22
M136 L −0.81 0.17 0.18
Q139R −1.06 −0.99 1.59
T131S,M136 L,Q139R NA NA −0.3
Prediction from mCSM and FoldX are shown changes for the in the EBOV
VP24 –KPNA5 complex
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stabilisation of the complex. In both the wild type Ebola
virus and Reston virus VP24-KPNA5 complexes high-
density grid points were found close to the residues
E203, P204 and D205. This means that these residues
are important in enhancing the stability of both com-
plexes while establishing favourable interactions with
water molecules. These residues belong to a loop inter-
acting with KPNA5 defining a cavity where the water
molecules are trapped.
The presence in the Reston VP24-KPNA5 complex of
high-density grid points, where water molecules are trapped,
suggests that part of the interface between Reston virus
VP24 and KPNA5 may be relatively stable compared to the
R137A-mutated Ebola virus VP24-KPNA5 complex, where
only low density grid points were observed, indicating
an absence of water molecules that would stabilise the
complex (Fig. 3).
Correlation of conformational changes in the Reston
virus VP24-KPNA5 complex was compared to the re-
sults for the wild type and R137A mutant Ebola virus
VP24-KPNA5 complexes. No correlated motions were
detectable in the simulation of the Reston virus complex
variant of the VP24-KPNA5 complex (Fig. 4c), whereas
many were observed for the Ebola virus VP24-KPNA5
complex and fewer for the Ebola virus R137A VP24-
KPNA5 complex (see above). Correlation of the conform-
ational changes analysis supported this with the Ebola
virus VP24-KPNA5 complex having a denser network of
inter-subunit correlations than did the Reston virus VP24-
KPNA5 complex, which reflects the results obtained for
Fig. 5 Hydrogen bonding in the Ebola and Reston virus VP24 complexes with KPNA5. VP24 hydrogen bonding with KPNA5 in the region of
residues R137-R140. Top two panels are for VP24 with the initial minimised structure (left) and the structure at the end of the simulation (right).
Bottom panels show the equivalent for Reston VP24. In all images VP24 is coloured grey
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the R137A mutant Ebola virus VP24-KPNA5 complex
(Fig. 4). Taken together, these findings suggest that Reston
virus VP24 forms a less stable complex with KPNA5 than
Ebola virus VP24, in particular due to the similarity of the
results obtained for Reston virus VP24 and R137A-
mutated Ebola virus VP24, which is known not to bind
human KPNA5 [3].
Discussion
This study investigated the dynamics of interaction of
the Ebolavirus protein VP24 with human KPNA5. This
interaction occurs during infection to prevent transport
of STAT1 to the nucleus in order to inhibit interferon
signaling [3–5]. Recent findings have identified positions
that are differentially conserved between human-pathogenic
Ebolaviruses and Reston virus, the only Ebolavirus that is
not pathogenic to humans [8]. In particular three of these
positions in the interface site between VP24 and human
KPNA5 were suggested to affect binding of Reston virus
VP24 to KPNA5 and to contribute to the lack of human
pathogenicity of Reston viruses [8].
Experimental evidence showed the R137A mutation in
Ebola virus VP24 to reduce VP24 binding to human
KPNA5 [3]. Therefore, we compared the Ebola virus
VP24-KPNA5 interaction with the R137A-mutant Ebola
virus VP24-KPNA5 interaction to validate our system. In
concert with the experimental findings [3], our analysis
predicted that the R137A mutation reduces VP24-KPNA5
binding. Moreover, the correlations of conformational
changes and solvation analysis provide novel molecular in-
sights into how this mutation affects binding of the two
proteins. They show that the mutation reduces the stabil-
ity of the complex, enables the two proteins to move apart
from each other, and for water to enter the interface.
The investigation of the interaction of Reston virus
VP24 with human KPNA5 added further evidence that
Reston VP24 is a weaker binding partner to human
KPNA5 than Ebola virus VP24. This is most strongly sug-
gested by the lack of correlated conformational move-
ments between Reston virus VP24 and KPNA5. Some
permanent water molecules are (in contrast to the R137A-
mutated Ebola virus VP24-KPNA5 complex) observed in
the interface of the Ebola virus VP24- and Reston Virus
VP24-KPNA5 complexes. This indicates some differences
between the interaction of R137A-mutated Ebola virus
VP24 and Reston virus VP24 with human KPNA5.
Conclusion
In conclusion, our results suggest that Reston virus
VP24 forms a weaker complex with human KPNA5 than
Ebola virus VP24. This weaker binding is anticipated to
reduce (in comparison to Ebola virus VP24) the capacity
of Reston virus VP24 to inhibit KPNA5-mediated STAT1
transport into the nucleus and to anatagonise interferon
signalling in human cells. This reduced Reston virus
VP24-KPNA5 complex stability is likely to contribute to
the lack of human pathogenicity observed in Reston
viruses. Hence, our findings contribute novel evidence
indicating VP24 to be an important regulator of species-
specific Ebolavirus pathogenicity, as previously suggested
by the analysis of conserved differences between Reston vi-
ruses and human-pathogenic Ebolaviruses [8]. In addition,
our findings provide novel mechanistic insights at the mo-
lecular level on the interaction of Ebolavirus VP24 with
human KPNA5.
Methods
Modelling of a RESTV-VP24 KPNA5 complex
The Ebola and Reston virus VP24 sequences share 81.3%
sequence identity and 96% similarity. The protein struc-
tures were aligned using Chimera [14] and a model for
Reston VP24 in complex with human KPNA5 built using
MODELLER 9.0 [15]. The Reston virus VP24 crystal
structure (PDB 4D9O) and the Ebola virus VP24-KPNA5
complex (PDB 4U2X) were used as templates for the
Reston virus complex model. 200 models were obtained
and the one with the lowest DOPE score was selected.
Comparison of interfaces
PISA [9] and mCSM [9] were used to analyse the structural
properties at the complexe interfaces, including solvent ac-
cessibility and binding affinity. FoldX [10] was used to pre-
dict the effects of the changes in Energy upon mutation, in
terms of effects in protein stability. POPSCOMP [16] was
used to determine the contribution of the individual
residues to the hydrophilicity and hydrophobicity at the
interface, according to their solvent accessible surface
area (SASA), using default parameters. The residues
were classified as being part of the core, support or rim
regions of the interface according to the change in
SASA (when the percentage of hydrophobicity was
greater than 40 and difference in SASA was less than
10 Å2 the residue was considered as core, otherwise it
was rim).
Molecular dynamics simulations
Molecular dynamics simulations were performed for the
wild type forms of Ebola virus VP24 and Reston virus
VP24 in complex with human KPNA5. Other simulations
were performed on the Ebola virus VP24-KPNA5 complex
with mutations introduced into VP24 where the effect on
KPNA5 binding had been experimentally determined [3].
The mutations considered were: 1)R137A, 2)Q139A,
3)F134A,M136A and 4) R137A-Q139A.
Molecular dynamics simulations were performed using
Gromacs 5.0.5 [17]. The procedure used has been previ-
ously described [16]. Briefly, starting structured were
solvated in a cubic box of SPC water and the distance
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between the protein and box boundaries was set to a
minimum of 12 Å. The standard protonation state
(pH 7) for ionisable residues was used, with counterions
used to neutralise the system. The GROMOS 53a6 par-
ameter set [18] was used. Periodic boundary conditions
were imposed. Temperature and pressure regulation was
performed using the Berendsen algorithm [19] using
coupling constants of 0.2 and 1 ps respectively. The
Ewald method [20] (particle mesh) was used to calculate
electrostatic interactions. The neighbour list for non-
covalent interactions were updated every five steps. The
first minimisation used the 1000 steps of steepest des-
cent. Harmonic positional restraints were applied to the
Heavy atoms in the protein (initially 4.8 kcal/mol/Å-2,
reduced to 1.24.8 kcal/mol/Å-2) and the temperature (at
constant volume) increased from 200 K to 300 K. The
simulation was then performed for 100 ps at constant
temperature and pressure (300 K and 1 bar). System
coordinates were saved every 1 ps.
We selected the force field GROMOS 53a6 because is
the latest version of the widely used force field [21] from
the GROMOS family stemming from the most widely
used GROMOS 43A1. These parameter sets are often
selected in performance studies where force fields are
assessed and compared [22–25], and where it is shown
that it is still one of the best united-atom force fields
available, providing in some cases even better results
than some all-atom force fields. Additionally, it is known
since a while that the 43A1 parameter set provides bet-
ter alpha/beta relative stabilities than GROMOS param-
eter sets developed later [26].
600 ns MD trajectories were obtained for the Ebola
virus VP24-KPNA5 complex and the model of the Reston
virus VP24-KPNA5 complex. In our analysis, we omitted
the first 280 ns of the simulation, as this was the approxi-
mate time required for each of the systems to reach con-
formational equilibrium. 200 ns trajectories were obtained
for R137A and F134A, M136A and 100 ns for all other
simulations.
Molecular dynamics analysis
Trajectories were analysed using the GROMACS analysis
tools, VMD tools and the Bio3D package for R [27, 28].
For the analysis, standard Periodic Boundary Conditions
were removed and Minimum Image Convention (MIC)
were applied to all the trajectories. Rotational and transla-
tional movements were then deleted in order to perform
the Principal Component Analysis. Secondary structure
plots for trajectories were obtained using the DSSP [29]
tool in gromacs. Root mean square deviation (RMSD) and
fluctuation (RMSF) from the initial starting complex were
obtained using Bio3D, as well as the PCA analysis and
correlation plots.
Analysis of correlation of conformational changes
We used a fragment-based approach to simplify the local
structure of each of the three molecular dynamics simu-
lations. The structural alphabet M32 K25 was used to
encode fragments of four consecutive Cα atoms, so as to
describe backbone conformations of the protein in a
simplified manner [12]. Mutual information between
two sets of fragments (i,j) was used to calculate the cor-
relation in conformational changes using a numerical
procedure outlined in [12]:
In ¼ I Ci;Cj
 
− Ci; Cj
 
H Ci;Cj
 
where Ci and Cj are columns in the structural string
alignment, I(Ci;Cj) is the mutual information, H(Ci;Cj) is
the joint entropy and ε(Ci;Cj) is the error.
Considering the fragment at positions Ci and Cj as a
discrete distribution of fragments X and Y, we calculated
the joint entropy H(X,Y) as a pair of discrete random
variables (X,Y) with a joint distribution p(x,y) defined as
H X;Yð Þ ¼ −
X
xεX
X
yϵY
p x; yð Þlogp x; yð Þ
where p(x) and p(y) are the associated marginal probabilities.
Analysis of solvation in the interaction surface
To perform the water density analysis, structures were
simulated, as previously described, for 5 ns by MD with
backbone restraints (1.2 kcal· mol − 1· Å − 2) to avoid
any significant conformational changes of the protein
during the simulation [11, 27]. Water density maps were
calculated at discrete points r defined by a 0.5-Å spaced
rectangular grid around the solute. To remove the overall
roto-translational motion of the protein the structures of
the last 10 ns of the trajectory were superimposed to a ref-
erence. From snapshots taken every 0.1 ps, the density of
the water oxygen atoms was averaged for each grid point
and normalised by the bulk density evaluated in a 6–8 Å
shell around the solute. The hydration score Shyd was
defined by identifying hydration sites as the local maxima
of the density map with g(r) > 1 as previously described
[30]. Water density maps were calculated for representa-
tive conformations of the Ebola virus VP24-KPNA5 com-
plex as extracted from the trajectory and compared to the
solvent distribution for the representative conformations
of Ebola virus R137A VP24-KPNA5 and Reston virus
VP24-KPNA5 complex trajectories.
A good water model to use as a solvent in biomolecu-
lar simulations should be computationally efficient and
at the same time reproduce accurately enough the prop-
erties of bulk water. Not to be underestimated, this
model should be compatible with the force field used for
the solute interactions. It is well known that simple
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effective pair potentials such as SPC, TIP3P and TIP4P
are, in different measure, not able to accurately describe
the entire range of water properties, nevertheless, they
have all proven to successfully model water as a solvent
in biomolecular simulations.
The general weakness demonstrated by these models is
in the overestimation of the diffusion coefficient and the
inaccurate description of the dielectric properties. On the
other hand they are effective in the calculation of solute
solvent energies and practical to use. In the past we have
developed solvent density maps based on the SPC model
[30, 31]. We were particularly interested in the water-
protein interactions due to the localization of water at the
surface of the protein, therefore we used the same model
in this application as a matter of consistency with the
force field and our previous calculations.
Additional file
Additional file 1: contains Figures. S1-S4. Legends for each of the
figures are provided below: Figure S1. RMSD curves for VP24 KPNA5
complex trajectories. A) Ebola (black line) and Reston (red line) in
complex with KPNA5 are shown. The Reston complex showed a higher
RMSD that could be explained with the suboptimal binding between the
two monomers (red line), while the EBOV complex showed a lower
RMSD during the whole 600 ns trajectory, meaning a greater stability of
the complex. B) For Ebola VP24 in complex with KPNA5 for wild type and
the set of mutated Ebola VP24 proteins. Figure S2. DSSP graphs for the
two wild type complexes. On the left side of the graph, the evolution of
the EBOV secondary structure is shown in EBOV VP24 (on the top) and
KPNA5 (on the bottom). On the right side, the evolution of the RESTV
secondary structure is shown for RESTV VP24 (on the top of the graph)
and KPNA5 (on the bottom). Residues at the interfaces are mapped in
yellow circles. Figure S3. Local error of structural alphabet fit. The RMSD
distribution per fragment position was calculated for a) WT EBOV VP24
and KPNA5, b) R137A EBOV VP24 and KPNA5 and c) RESTV VP24 and
KPNA5. Figure S4. Hydrogen bonding in the Ebola and Reston virus
VP24 complexes with KPNA5. Probability distribution of the number of H-
bonds at the interface during the simulation for Ebola virus VP24- KPNA5
complex (black) and for Reston virus VP24- KPNA5 (red). (PDF 1132 kb)
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